Health Care·Health Care Equipment·$32.0B
ResMed Inc. (RMD) operates in the health care sector, focusing on equipment and software solutions for people with sleep apnea and other chronic respiratory conditions....
EPS
Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.
Revenue
Total revenue reflects the company's sales performance and overall market demand for its products and services.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
8Q
EPS Beat Rate
100%
Avg EPS Surprise
+4.80%
Avg Stock Reaction
+0.08%
In Q2 2026, ResMed reported an EPS of $2.81, exceeding expectations by 4.58%. However, revenue details were not disclosed, leaving some uncertainty about overall performance.
Management Promises & Guidance
Analysts expect ResMed to maintain its strong earnings trajectory with a consensus EPS of $2.81. The market is keenly watching for any signs of revenue growth and operational efficiency.
Bull Case
If ResMed can deliver better-than-expected revenue and maintain its EPS beat streak, it could signal strong demand and effective cost management, boosting investor confidence.
Bear Case
Conversely, if the company fails to meet revenue expectations or provides weak guidance, it could raise concerns about market saturation and competitive pressures.
EPS
$2.81Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.
Revenue
$1.4BTotal revenue reflects the company's sales performance and overall market demand for its products and services.
The print will turn on these two things.
Q1
What is the revenue growth rate compared to last year?
This will indicate whether ResMed is successfully expanding its market presence and meeting demand.
Q2
How is the company addressing competitive pressures in the respiratory market?
Understanding ResMed's strategy in a competitive landscape will be crucial for assessing future growth potential.
Why consensus could be wrong
The consensus may underestimate ResMed's ability to capture market share in emerging markets, which could drive stronger revenue growth than anticipated.
Supporting Evidence
Historical performance shows ResMed consistently beats EPS estimates, indicating strong operational management.
Options pricing suggests a larger potential move than what has been realized in the past, hinting at possible upside.
Management's commitment to innovation and digital health solutions could enhance competitive positioning.
Key Risk
If revenue growth exceeds 10%, it could challenge current market expectations and shift sentiment significantly.
Pre-commit to what would confirm each case.
The core debate centers around ResMed's ability to sustain growth in a competitive health care equipment market.
Bull Confirmed If
Revenue growth of at least 10% year-over-year would confirm strong market demand and operational efficiency.
Bear Confirmed If
Any revenue decline or guidance below $1.4B would raise significant concerns about market saturation and competitive pressures.
Implied Move
±4.64%
Historical Avg
±0.77%
The options market is pricing in a significant move around the earnings announcement, indicating heightened investor uncertainty or anticipation.
Options price a 4.64% move but the stock has averaged only 0.77% over the last 8 quarters — setup is rich.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If ResMed beats expectations, history suggests the stock could see a modest increase of around +0.08%, confirming strong demand.
In-Line / Cautious
If results are in line with expectations, the market may react cautiously, leading to minimal movement as investors await further guidance.
Miss
A miss could lead to a decline, with historical patterns suggesting a potential drop of around -0.54%.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
VERIZON COMMUNICATIO
Apr 27, 2026